As of close of business last night, Spero Therapeutics Inc’s stock clocked out at $1.73, down -3.35% from its previous closing price of $1.79. In other words, the price has decreased by -$0.0600 from its previous closing price. On the day, 895153 shares were traded. SPRO stock price reached its highest trading level at $1.7799 during the session, while it also had its lowest trading level at $1.6500.
Ratios:
To gain a deeper understanding of SPRO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.53 and its Current Ratio is at 3.53. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Evercore ISI on September 23, 2022, Upgraded its rating to Outperform and sets its target price to $8 from $2 previously.
H.C. Wainwright reiterated its Buy rating for the stock on January 22, 2021, while the target price for the stock was revised from $33 to $40.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 05 ’24 when Shukla Sath sold 45,093 shares for $1.45 per share. The transaction valued at 65,385 led to the insider holds 1,176,007 shares of the business.
Mahadevia Ankit sold 63,795 shares of SPRO for $87,399 on Feb 02 ’24. The Director now owns 744,997 shares after completing the transaction at $1.37 per share. On Feb 02 ’24, another insider, JOSEPH TAMARA L, who serves as the Chief Legal Officer of the company, sold 30,906 shares for $1.37 each. As a result, the insider received 42,341 and left with 531,615 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SPRO now has a Market Capitalization of 93.19M and an Enterprise Value of 22.40M. As of this moment, Spero’s Price-to-Earnings (P/E) ratio for their current fiscal year is 4.08. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.11. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.96 while its Price-to-Book (P/B) ratio in mrq is 0.86. Its current Enterprise Value per Revenue stands at 0.23 whereas that against EBITDA is 0.87.
Stock Price History:
Over the past 52 weeks, SPRO has reached a high of $2.00, while it has fallen to a 52-week low of $0.99. The 50-Day Moving Average of the stock is 1.5447, while the 200-Day Moving Average is calculated to be 1.3903.
Shares Statistics:
It appears that SPRO traded 304.21K shares on average per day over the past three months and 823.52k shares per day over the past ten days. A total of 53.00M shares are outstanding, with a floating share count of 35.96M. Insiders hold about 33.25% of the company’s shares, while institutions hold 21.24% stake in the company. Shares short for SPRO as of Feb 29, 2024 were 564k with a Short Ratio of 1.85, compared to 707.12k on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.06% and a Short% of Float of 1.30%.
Earnings Estimates
As of right now, 3 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.12 for the current quarter, with a high estimate of $0 and a low estimate of -$0.34, while EPS last year was -$0.25. The consensus estimate for the next quarter is -$0.41, with high estimates of -$0.32 and low estimates of -$0.47.
Analysts are recommending an EPS of between -$0.49 and -$0.99 for the fiscal current year, implying an average EPS of -$0.75. EPS for the following year is -$0.74, with 3 analysts recommending between -$0.26 and -$1.06.
Revenue Estimates
In the current quarter, 3 analysts expect revenue to total $16.93M. It ranges from a high estimate of $24M to a low estimate of $3M. As of the current estimate, Spero Therapeutics Inc’s year-ago sales were $1M, an estimated increase of 1,593.00% from the year-ago figure.
A total of 3 analysts have provided revenue estimates for SPRO’s current fiscal year. The highest revenue estimate was $52M, while the lowest revenue estimate was $47.5M, resulting in an average revenue estimate of $49.17M. In the same quarter a year ago, actual revenue was $103.78M, down -52.60% from the average estimate. Based on 2 analysts’ estimates, the company’s revenue will be $47.75M in the next fiscal year. The high estimate is $48M and the low estimate is $47.5M. The average revenue growth estimate for next year is down -2.90% from the average revenue estimate for this year.
